NEOS Investment Management LLC Has $2.43 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH

NEOS Investment Management LLC increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 45.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,681 shares of the medical equipment provider’s stock after acquiring an additional 7,719 shares during the period. NEOS Investment Management LLC’s holdings in Zimmer Biomet were worth $2,431,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Brighton Jones LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $204,000. Sivia Capital Partners LLC acquired a new stake in Zimmer Biomet in the 2nd quarter valued at approximately $232,000. Nordea Investment Management AB raised its position in Zimmer Biomet by 7.3% in the 2nd quarter. Nordea Investment Management AB now owns 17,839 shares of the medical equipment provider’s stock valued at $1,628,000 after buying an additional 1,210 shares during the last quarter. Private Trust Co. NA lifted its stake in Zimmer Biomet by 14.6% in the 2nd quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock valued at $98,000 after acquiring an additional 137 shares in the last quarter. Finally, United Bank boosted its position in Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after acquiring an additional 1,153 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Robert W. Baird reiterated a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. BTIG Research reiterated a “buy” rating and issued a $112.00 price target on shares of Zimmer Biomet in a research note on Tuesday, February 10th. UBS Group restated a “sell” rating and set a $89.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $100.00 target price (down previously from $115.00) on shares of Zimmer Biomet in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $99.17 on Friday. The company has a market cap of $19.65 billion, a PE ratio of 28.01, a price-to-earnings-growth ratio of 2.01 and a beta of 0.62. The firm has a 50-day moving average of $90.50 and a 200-day moving average of $95.78. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.Zimmer Biomet’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the company posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Tuesday, December 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.